ALSO NOTED: Osiris files IPO; Amgen initiates kidney disease study; and much more...

> Baltimore-based stem cell therapeutic company Osiris Therapeutics announced an IPO at 3.5 million shares for about $11 to $13 each. Report

> Chutes & Ladders: Ann, Arbor, MI-based Aastrom Biosciences has named George W. Dunbar CEO and president. Release

> Melbourne-based CSL Limited will acquire biotech Zenyth Therapeutics for about $108 million. Release

> Amgen is initiating a 3,800-person study of Sensipar/Mimpara for kidney disease. Report

And Finally... The Senate will continue to debate three stem cell bills which President Bush has pledged to veto if passed. Article (WSJ sub. req.)

Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.